Nestihnout vyhořet

doc. MUDr. Petra Tesařová, CSc.

Onkologie. 2014:8(3):99  

Hodgkinův lymfom - slovo úvodem

Tomáš Papajík

Onkologie. 2014:8(3):101  

The possibilities of the diagnostics of the CD5-positive B-lymphoproliferative disorders

David Starostka, Peter Mikula

Onkologie. 2014:8(3):102-106  

CD5+ B-lymphoproliferative disorders represent a significant group of the defined diagnostic entities within the framework of the WHO classification of mature B-cell neoplasms. The pathological presence of CD5 antigen is an important diagnostic feature because of the minor expression of CD5 on normal B-lymphocytes. The laboratory diagnostics of the CD5+ B-lymphoproliferative disorders is multidisciplinary and it comprises the morphological methods (cytology, histology), the methods of immunophenotyping (immunohistochemistry, flow cytometry) and the cytogenetic and molecular cytogenetic methods. Based on the morphological features, the immunophenotype...

Benefit of early PET/CT for prognostic stratification and treatment of patients with diffuse large B cell lymphoma

Zuzana Kapitáňová, Lenka Henzlová, Eva Buriánková, Aleš Obr, Miroslav Mysliveček, Tomáš Papajík

Onkologie. 2014:8(3):107-111  

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid neoplasia, and for modern therapeutic approaches is a highly curable cancer. In the era of immunochemotherapy there is still a significant group of patients who are primarily refractory to a therapy or relapse after treatment. Result early PET/CT (ePET/CT) during therapy can be a valuable indicator of tumor sensitivity to a given treatment. The assessment of ePET/CT today are quite broad and include both visual description, as well as different methods semiquantitative assessment of treatment response. Despite the amount of data acquired so far and the number of promising preliminary...

Treating localized stage of Hodgkin's lymphoma

Zdeněk Král

Onkologie. 2014:8(3):112-116  

The current therapeutic strategy for localized clinical stage of Hodgkin's lymphoma is based on dividing the patients according to the presence of risk factors into groups with favourable and poor prognosis. The two groups differ in treatment intensity, with patients with a poor prognosis being administered more chemotherapy and a higher dose of irradiation. In order to reduce late toxicity of radiotherapy, particularly secondary malignancies, extended-field radiotherapy, EFRT, has been replaced with a technique with a lower target volume, IFRT.

Current treatment approaches in patients with advanced-stage Hodgkin lymphoma

Heidi Móciková

Onkologie. 2014:8(3):117-120  

More than 80 % of patients with Hodgkin lymphoma (HL) younger than 60 years are likely to be cured with modern treatment strategies. The goal of current treatment approaches is to maintain the high treatment efficacy and to reduce the toxicity. BEACOPP escalated has a 10 % overall survival advantage over ABVD in patients with advanced-stage HL, therefore 6 cycles of BEACOPP escalated has become the standard of care for patients younger than 60 years. Six cycles of ABVD remain the standard of care for patients over 60 years. Radiotherapy could be omitted in patients with a negative positrone emission tomography (PET) finding after chemotherapy....

Allogeneic stem cell transplantation in treating haematological malignancies in children

Petr Sedláček, Petr Říha

Onkologie. 2014:8(3):121-123  

Allogeneic haematopoietic stem cell transplantation is a therapeutic method in a wide range of malignant or non-malignant diseases. Healthy cells of a suitable donor replace missing, malignant, or non-functional recipient's cells. The donor's immune system ensures protection from infections while reducing the risk of disease recurrence. However, it can cause damage to the recipient's healthy tissue (graft-versus-host disease). The sources of stem cells can include the bone marrow, stimulated peripheral blood stem cells, or umbilical- -cord blood from a suitable related or anonymous donor from a registry.

Systemic therapy in the bone sarcoma treatment

Dagmar Adámková Krákorová, Štěpán Tuček

Onkologie. 2014:8(3):124-128  

Bone sarcomas are extremely rare neoplasms. Early diagnosis and effective treatment are significant for the therapy achievment. According to the high specialization, multidisciplinary treatments planning by an experienced team is mandatory in all cases of bone sarcoma.

Discontinuation of biological therapy with tyrosine kinase inhibitors in chronic myeloid leukemia patients

Pavel Dvořák, Daniel Lysák, Samuel Vokurka, Věra Vozobulová

Onkologie. 2014:8(3):129-130  

Imatinib mesylate, the first tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML), became the standard of care, induces durable responses and prolongs event-free survival and progression-free survival. However, if TKI therapy is required indefinitely, then this ongoing drug exposure raises its own problems. Long-term follow-up indicates that an increasing proportion of patients treated with TKI have prompt cytogenetic response and achieve reductions in BCR-ABL1 transcripts to a level that is undetectable by very sensitive molecular genetic methods. Observation of the stability of such responses over long...

Extramedullary relapse of acute leukemia in the breast after allogeneic stem cell transplantation

Peter Rohoň, Zuzana Rusiňáková, Luděk Raida, Zuzana Prouzová, Tomáš Szotkowski, Jaromír Hubáček, Martina Divoká, Lucia Veverková, Kateřina Spáčilová, Zuzana Pikalová, Marie Jarošová, Edgar Faber, Karel Indrák

Onkologie. 2014:8(3):131-134  

Extramedullary (EM) manifestation of acute myeloid leukemia (AML) is relatively rare, it occurs frequently in 2 forms: myeloid sarcoma (MS) or leukemia cutis (LC). The molecular mechanism of EM involvement has not been clearly explained yet, but it is obvious that homing of leukemic cells to peripheral tissues is controlled by chemokine receptors, adhesion molecules and their interactions. The isolated EM relapse (IEMR) after allogeneic haematopoietic stem cell transplantation (ASCT) is an uncommon clinical manifestation with an unfavourable prognosis, especially in case of systemic relapse. It is probably the result of GvL imbalance in the...

Toxicity of docetaxel treatment in patients with breast cancer

Kateřina Krošláková, Milan Kohoutek, Markéta Pospíšková

Onkologie. 2014:8(3):136-138  

Docetaxel is a cytostatic drug used in adjuvant, neoadjuvant as well as palliative treatment of breast cancer. It is administered as monotherapy or as part of combination regimens. Taxanes along with anthracyclines are among the most efficacious chemotherapeutic drugs used in the treatment of breast cancer. Inclusion of docetaxel in the therapeutic regimen for breast cancer has resulted in improved overall survival and extended disease-free interval in patients treated with adjuvant therapy and in a greater proportion of therapeutic responses as well as extended time-to-progression and overall survival with palliative therapy (1, 2, 3, 4, 5)....

Brněnské sympozium o intravenózním podávání vysokodávkovaného vitaminu C onkologickým pacientům

Onkologie. 2014:8(3):139-142